A 12-week, double-blind, placebo-controlled, randomized, multicenter study of the efficacy of 40 mg/day KW-6002 [istradefylline] as treatment for Parkinson's disease in patients with motor response complications on levodopa/carbidopa therapy
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Istradefylline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kyowa Kirin Pharmaceutical Development
- 01 Mar 2008 Results have been published in the Annals of Neurology.
- 16 Apr 2007 New trial record.